Ricardo Dolmetsch

1.1k total citations · 1 hit paper
2 papers, 660 citations indexed

About

Ricardo Dolmetsch is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Toxicology. According to data from OpenAlex, Ricardo Dolmetsch has authored 2 papers receiving a total of 660 indexed citations (citations by other indexed papers that have themselves been cited), including 1 paper in Molecular Biology, 1 paper in Cellular and Molecular Neuroscience and 1 paper in Toxicology. Recurrent topics in Ricardo Dolmetsch's work include Neurotransmitter Receptor Influence on Behavior (1 paper), Neuroscience and Neuropharmacology Research (1 paper) and Forensic Toxicology and Drug Analysis (1 paper). Ricardo Dolmetsch is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (1 paper), Neuroscience and Neuropharmacology Research (1 paper) and Forensic Toxicology and Drug Analysis (1 paper). Ricardo Dolmetsch collaborates with scholars based in Switzerland, United States and Argentina. Ricardo Dolmetsch's co-authors include Ranjit Randhawa, Zinger Yang, John Reece-Hoyes, Chaoyang Ye, Kraig M. Theriault, Gregory McAllister, Kathleen A. Worringer, William C. Forrester, Max R. Salick and Daniel Ho and has published in prestigious journals such as Nature Medicine and Science Translational Medicine.

In The Last Decade

Ricardo Dolmetsch

2 papers receiving 645 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells

2018 658 citations Robert J. Ihry, Kathleen A. Worringer et al. Nature Medicine profile →

Peers

Countries citing papers authored by Ricardo Dolmetsch

Since Specialization

Citations

This map shows the geographic impact of Ricardo Dolmetsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ricardo Dolmetsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ricardo Dolmetsch more than expected).

Fields of papers citing papers by Ricardo Dolmetsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ricardo Dolmetsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ricardo Dolmetsch. The network helps show where Ricardo Dolmetsch may publish in the future.

Co-authorship network of co-authors of Ricardo Dolmetsch

This figure shows the co-authorship network connecting the top 25 collaborators of Ricardo Dolmetsch. A scholar is included among the top collaborators of Ricardo Dolmetsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ricardo Dolmetsch. Ricardo Dolmetsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

2 of 2 papers shown

#	Work	Indexed citations
1	Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial 2025 ·Science Translational Medicine ·Baltazar Gomez‐Mancilla, Kenneth M. Dürsteler, Marc Vogel, Marcus Herdener, Marta Torrens, (unknown), Antoni Gual, Ricardo Corral, (unknown), (unknown), (unknown), Nicole Pezous, (unknown), (unknown), (unknown), Jang‐Ho Cha, Ricardo Dolmetsch	2
2	p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells breakdown → 2018 ·Nature Medicine ·Robert J. Ihry, Kathleen A. Worringer, Max R. Salick, Elizabeth Frias, Daniel Ho, Kraig M. Theriault, Sravya Kommineni, Julie Chen, Marie Sondey, Chaoyang Ye, Ranjit Randhawa, (unknown), Zinger Yang, Gregory McAllister, Carsten Russ, John Reece-Hoyes, William C. Forrester, Gregory R. Hoffman, Ricardo Dolmetsch, Ajamete Kaykas	658

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact